This trial is active, not recruiting.

Condition healthy
Sponsor University of Minnesota - Clinical and Translational Science Institute
Collaborator National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Start date November 2012
End date November 2017
Trial size 30 participants
Trial identifier NCT02053701, 1210M23141, P41EB015894


Magnetic resonance spectroscopy (MRS) allows non-invasive measurement of the concentration of up to 18 metabolites in the brain ("neurochemical profile").

The objective of this proposal is to develop new methods for high-field brain MRS (3 to 7 Tesla).

Our main hypothesis is that higher magnetic fields lead to improved spatial and temporal resolution and improved quantification precision.


1. To obtain improved "neurochemical profiles" in the brain using single voxel proton MRS at very high field (3 Tesla to 7 Tesla).

2. To develop new methods for proton magnetic resonance spectroscopic imaging (MRSI) to obtain metabolic maps at very high field (3 Tesla to 7 Tesla).

Since this project is focused on technical development, only healthy volunteers will be recruited (no patients).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model other
Time perspective other

Primary Outcomes

Precision of quantification of brain metabolites concentrations
time frame: One time only

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - over 18 years old Exclusion Criteria: - no metallic implant or other MRI-incompatible device

Additional Information

Official title Technical Developments for High-field Brain Magnetic Resonance Spectroscopy
Principal investigator Pierre-Gilles Henry, PhD
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by University of Minnesota - Clinical and Translational Science Institute.